Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors
In an exclusive interview with The Fly, Lyell (LYEL) CEO Liz Homans talked about the company, its pipeline, upcoming milestones, going public, and much more.
TECHNOLOGY PLATFORMS: Lyell is a T-cell reprogramming company, focusing on addressing what it believes are the primary barriers that limit consistent, reliable, and curative responses to adoptive T-cell therapy, namely T-cell exhaustion and lack of durable stemness. “The two reprograming technologies that are clinic ready are Gen-R and Epi-R. Gen-R is short for genetic reprograming and addresses T-cell exhaustion, this dysfunctional state t-cells enter into when they encounter a solid tumor micro environment. Gen-R is based on the work Crystal Mackall did at Stanford University. Crystal is a founder of Lyell. What Crystal discovered was that exhausted t-cells have an imbalance in the AP-1 family of transcription factors and if you rebalance those cells, you can endow them with the ability to resist exhaustion. That’s what the Gen-R technology does. We genetically reprogram the cells so they can resist exhaustion,” CEO Liz Homans explained to The Fly.
To see the rest of the story Click Here.